Phase 3 Study of TS-071 in Patients With Type 2 Diabetes Mellitus (Double-blind, Parallel Group, Placebo-Controlled Study)
Latest Information Update: 27 Sep 2021
At a glance
- Drugs Luseogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Taisho Pharmaceutical
- 12 Sep 2021 Results of pooled analysis of three studies JapicCTI090908, JapicCTI101191 and JapicCTI11166116 published in the Journal of Clinical Pharmacology
- 02 Oct 2013 New trial record
- 26 Sep 2013 Results reported at 49th Annual Meeting of the European Association for the Study of Diabetes (EASD), according to a Taisho Pharmaceutical Holdings media release.